Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics

Author(s): Jose F. Abisambra, Umesh K. Jinwal, Jeffrey R. Jones, Laura J. Blair, John Koren III, Chad A. Dickey

Journal Name: Current Neuropharmacology

Volume 9 , Issue 4 , 2011

Become EABM
Become Reviewer
Call for Editor


The heat shock protein (Hsp) family is an evolutionarily conserved system that is charged with preventing unfolded or misfolded proteins in the cell from aggregating. In Alzheimers disease, extracellular accumulation of the amyloid β peptide (Aβ) and intracellular aggregation of the microtubule associated protein tau may result from mechanisms involving chaperone proteins like the Hsps. Due to the ability of Hsps to regulate aberrantly accumulating proteins like Aβ and tau, therapeutic strategies are emerging that target this family of chaperones to modulate their pathobiology. This article focuses on the use of Hsp-based therapeutics for treating primary and secondary tauopathies like Alzheimers disease. It will particularly focus on the pharmacological targeting of the Hsp70/90 system and the value of manipulating Hsp27 for treating Alzheimers disease.

Keywords: Heat shock proteins, chaperones, neurodegeneration, alzheimer, Hsp27, Tau, heat shock proteins (Hsps), 42-amino acid version, Alzheimer's disease

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [623 - 631]
Pages: 9
DOI: 10.2174/157015911798376226
Price: $65

Article Metrics

PDF: 7